A5016393893- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- RNA Interference and Gene Delivery
- Monoclonal and Polyclonal Antibodies Research
- vaccines and immunoinformatics approaches
- Immune Cell Function and Interaction
- CAR-T cell therapy research
- Hepatitis B Virus Studies
- Cancer Research and Treatments
- Nanoplatforms for cancer theranostics
- Virus-based gene therapy research
- Respiratory viral infections research
- Immune cells in cancer
- Phagocytosis and Immune Regulation
- Influenza Virus Research Studies
- Advanced Biosensing Techniques and Applications
- Single-cell and spatial transcriptomics
- Pneumonia and Respiratory Infections
- T-cell and B-cell Immunology
- Parvovirus B19 Infection Studies
- Tracheal and airway disorders
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Viral Infections and Outbreaks Research
- Vibrio bacteria research studies
- Reproductive System and Pregnancy
Immunovaccine (Canada)
2007-2018
Dalhousie University
2011-2017
Edinburgh Royal Infirmary
2011
DepoVax™ is an innovative and strongly immunogenic vaccine platform. Survivin highly expressed in many tumor types has reported prognostic value. To generate tumor-specific immune response, a novel cancer was formulated DepoVax platform (DPX-Survivac) using survivin HLA class I peptides. Safety potency of DPX-Survivac tested combination with immune-modulator metronomic cyclophosphamide ovarian patients. All the patients receiving therapy produced antigen-specific responses; higher dose...
DepoVax is a novel non-emulsion depot-forming vaccine platform with the capacity to significantly enhance immunogenicity of peptide cancer antigens. Naturally processed HLA-A2 restricted peptides presented by breast, ovarian and prostate cells were used as antigens create therapeutic vaccine, DPX-0907.A phase I clinical study was designed examine safety immune activating potential DPX-0907 in advanced stage patients. A total 23 late patients recruited divided into two dose/volume cohorts...
Chemotherapy has been a mainstay in cancer treatment for many years. Despite some success, the cure rate with chemotherapy remains unsatisfactory types of cancers, and severe side effects from these treatments are concern. Recently, understanding dynamic interplay between tumor immune system led to development novel immunotherapies, including vaccines. Cancer vaccines have advantageous features, but their use hampered by poor immunogenicity. Many developments increased potency pre-clinical...
Respiratory syncytial virus infection can cause lower respiratory tract in older adults comparable to influenza, but no vaccines are available.
In clinical trials, metronomic cyclophosphamide (CPA) is increasingly being combined with vaccines to reduce tumor-induced immune suppression. Previous strategies modulate the system during vaccination have involved continuous administration of low dose chemotherapy, studies that posed unique considerations for trial design. Here, we evaluated CPA in combination a peptide vaccine targeting HPV16E7 an HPV16-induced tumor model, focusing on cytotoxic T-cell response and timing (mCPA) treatment...
Melanoma tumors are known to express antigens that usually induce weak immune responses of short duration. Expression both tumor-associated p53 and TRP2 by melanoma cells raises the possibility simultaneously targeting more than one antigen in a therapeutic vaccine. In this report, we show VacciMax (VM), novel liposome-based vaccine delivery platform, can increase immunogenicity associated antigens, resulting tumor elimination.C57BL/6 mice bearing B16-F10 were vaccinated subcutaneously 6...
Purpose: MRI cell tracking can be used to monitor immune cells involved in the immunotherapy response, providing insight into mechanism of action, temporal progression tumour growth and individual potency therapies. To evaluate whether could track populations response immunotherapy, CD8+ cytotoxic T (CTLs), CD4+CD25+FoxP3+ regulatory (Tregs) myeloid derived suppressor (MDSCs) were labelled with superparamagnetic iron oxide (SPIO) particles. Methods: SPIO-labelled injected mice (one...
Future cancer immunotherapies will combine multiple treatments to generate functional immune responses antigens through synergistic, multi-modal mechanisms. In this study we explored the combination of three distinct immunotherapies: a class I restricted peptide-based vaccine, metronomic cyclophosphamide (mCPA) and anti-PD-1 treatment in murine tumor model expressing HPV16 E7 (C3).
Many pathogens use the same immune evasion mechanisms as cancer cells. Patients with chronic infections have elevated levels of checkpoint receptors (e.g., programed cell death 1, PD1) on T Monoclonal antibody (mAb)-based inhibitors to also been shown enhance T-cell responses in models infection. Therefore, potential act a vaccine "adjuvant" by facilitating expansion antigen-specific repertoires. Here, we report discovery and characterization peptide-based class PD1 inhibitors, which potent...
The incidence of cancer increases significantly in later life, yet few pre-clinical studies immunotherapy use mice advanced age. A novel vaccine delivery platform (VacciMax®,VM) is described that encapsulates antigens and adjuvants multilamellar liposomes a water-in-oil emulsion. therapeutic potential VM-based vaccines administered as single dose was tested HLA-A2 transgenic age (48–58 weeks old) bearing large palpable TC1/A2 tumors. contained one or more peptides having human CTL epitopes...
In light of lack efficacy associated with current cancer vaccines, we aimed to develop a novel vaccine platform called DepoVax as therapeutic for breast/ovarian cancer. This study was designed examine the this over conventional emulsion using human class I MHC transgenic mice. We have developed water-free depot formulation (DPX-0907) high immune activating potential. Naturally processed peptides bound HLA-A2 molecules isolated from independent breast and ovarian tumor cell lines, but not...
Vaccines that can rapidly induce strong and robust antibody-mediated immunity could improve protection from certain infectious diseases for which current vaccine formulations are inefficient. For indications such as anthrax influenza, antibody production in vivo is a correlate of efficacy. Toll-like receptor (TLR) agonists frequently studied their role adjuvants, largely because ability to enhance initiation immune responses antigens by activating dendritic cells. However, TLRs also...
Anthrax is a serious biological threat caused by pulmonary exposure to aerosolized spores of Bacillus anthracis. Biothrax® (anthrax vaccine adsorbed (AVA)) the only Food and Drug Administration-licensed requires five administrations over 12 months with annual boosting maintain pre-exposure prophylaxis. Here we report evaluation single intramuscular injection recombinant B. anthracis-protective antigen (rPA) formulated in DPX delivery platform. Immune responses were compared an alum-based...
Oil emulsions are commonly used as vaccine delivery platforms to facilitate slow release of antigen by forming a depot at the injection site. Antigen is trapped in aqueous phase and emulsion degrades vivo passively released. DepoVax™ unique oil based system that directly suspends components diluent forces immune cells actively take up from formulation absence passive release. The aim this study was use magnetic resonance imaging (MRI) with additional biological markers evaluate understand...
There is currently a lack of biomarkers to help properly assess novel immunotherapies at both the preclinical and clinical stages development. Recent work done by our group indicated significant volume changes in vaccine draining right lymph node (RLN) volumes mice that had been vaccinated with DepoVaxTM, lipid-based platform was developed enhance potency peptide-based vaccines. These (LN) were unique mice.To better potential volumetric LN markers for multiple vaccination platforms, we...
In the preclinical development of immunotherapy candidates, understanding mechanism action and determining biomarkers that accurately characterize induced host immune responses is critical to improving their clinical interpretation. Magnetic resonance imaging (MRI) was used evaluate in vivo changes lymph node size response a peptide-based cancer vaccine therapy, formulated using DepoVax (DPX). DPX novel adjuvant lipid-in-oil–based formulation facilitates enhanced by retaining antigens at...
The small hydrophobic (SH) glycoprotein of human respiratory syncytial virus (RSV) is a transmembrane protein that poorly accessible by antibodies on the virion but has an ectodomain (SHe) and expressed infected cells. SHe from RSV strain A been formulated in DPX, unique delivery platform containing adjuvant, being evaluated as vaccine candidate. proposed mechanism protection immune-mediated clearance cells rather than neutralization virion. Our phase I clinical trial data clearly showed...
DPX is a unique T cell activating formulation that generates robust immune responses (both clinically and preclinically) which can be tailored to various cancers via the use of tumor-specific antigens adjuvants. While DPX-based immunotherapies may act complementary with checkpoint inhibitors, combination therapy not always easily predictable based on individual therapeutic responses. Optimizing these combinations improved by understanding mechanism action underlying therapies. Magnetic...
3030 Background: Survivin, a protein involved in regulation of apoptosis, is highly expressed many tumor types and has reported prognostic value. DPX-Survivac cocktail survivin HLA class I peptides (A1, A2, A3, A24 B7) formulated the novel adjuvanting vaccine platform DepoVax. A phase study examined safety immune potency combination with cyclophosphamide ovarian cancer patients. Methods: 18 19 advanced patients treated platinum chemotherapy showing no disease progression completed their...
e13050 Background: Immunovaccine Inc. (IMV) has developed a novel liposome-in-oil depot vaccine platform called DepoVax (DPX), which increases the potency of peptide-based vaccines. DPX-0907 is DPX-based cancer vaccine, containing 7 HLA-A2 restricted peptides, designed to target antigens present in breast, ovarian and prostate cancer. The represent multi-targeted approach that focuses on pathways are critical for survival cell. IMV demonstrated preclinical models produces stronger better...
Peptide antigens are combined with an adjuvant in order to increase immunogenicity vivo. The and safety of a RSV vaccine formulated novel oil-based platform, DepoVax™ (DPX), was compared alum formulation. A peptide B cell epitope derived from small hydrophobic ectodomain (SHe) served as the antigen. Both vaccines induced SHe-specific antibodies after immunization mice. single dose DPX-based formulation resulted anti-SHe titres for up 20 weeks. Boosting Alum-SHe, but not DPX-SHe, led...
5555 Background: Survivin plays a key role in apoptosis, proliferation and angiogenesis. It is overexpressed 90% of epithelial OC making it an attractive target. Increases expression have been correlated with progression drug resistance. DPX-Survivac vaccine containing mix survivin HLA class I peptides designed to evoke cytotoxic T cell response against survivin. This Phase I/Ib de-escalation study reports the safety immune potency combination metronomic low dose oral cyclophosphamide (CPA)...